Literature DB >> 23993451

Differential profiles of immune mediators and in vitro HIV infectivity between endocervical and vaginal secretions from women with Chlamydia trachomatis infection: a pilot study.

Rhoda Sperling1, Thomas A Kraus, Jian Ding, Alina Veretennikova, Elizabeth Lorde-Rollins, Tricia Singh, Yungtai Lo, Alison J Quayle, Theresa L Chang.   

Abstract

Chlamydia trachomatis infection is one of the most prevalent bacterial STIs in the USA and worldwide, and women with C. trachomatis infection are at increased risk of acquiring HIV. Because immune activation at the genital mucosa facilitates HIV/SIV infection, C. trachomatis-mediated cytokine induction may contribute to increased HIV transmission in asymptomatic women. To begin to elucidate the mechanisms, we longitudinally analyzed profiles of innate immune factors and HIV infectivity in genital secretions from anatomically specific sites in asymptomatic women during C. trachomatis infection and post-antibiotic treatment. We found higher levels of cytokines and chemokines in endocervical secretions than vaginal secretions. Compared with the convalescent state, G-CSF, IL-1α, and RANTES were elevated in endocervical secretions, IFN-γ and TNF-α were elevated in vaginal secretions, and IFNγ, IL-1β, and MIP1-α were elevated in cervicolavage fluid (CVL), before adjustment of multiple comparisons. Elevated endocervical levels of IP-10 and MCP-1 were associated with the use of hormonal contraception in infected women after successful treatment, suggesting the role of hormonal contraception in inflammation independent of STIs. Importantly, soluble factors found in endocervical secretions during infection enhanced HIV infectivity while no difference in HIV infectivity was found with vaginal secretions or CVL during infection or at convalescence. Taken together, the profiles of immune mediators and in vitro HIV infectivity indicate that the endocervical and vaginal mucosa are immunologically distinct. Our results underscore the importance of considering anatomical site and local sampling methodology when measuring mucosal responses, particularly in the presence of C. trachomatis infection.
Copyright © 2013 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Chlamydia trachomatis; HIV infectivity in vitro.; HIV transmission; Immune mediators; Lower genital tract

Mesh:

Substances:

Year:  2013        PMID: 23993451      PMCID: PMC3874462          DOI: 10.1016/j.jri.2013.07.003

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  44 in total

Review 1.  Perils at mucosal front lines for HIV and SIV and their hosts.

Authors:  Ashley T Haase
Journal:  Nat Rev Immunol       Date:  2005-10       Impact factor: 53.106

2.  Interleukin (IL)-2 and IL-12 responses to Chlamydia trachomatis infection in adolescents.

Authors:  C Wang; J Tang; P A Crowley-Nowick; C M Wilson; R A Kaslow; W M Geisler
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

3.  Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells.

Authors:  R N Fichorova; D J Anderson
Journal:  Biol Reprod       Date:  1999-02       Impact factor: 4.285

4.  A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis.

Authors:  J R Schwebke; R A Desmond
Journal:  Clin Infect Dis       Date:  2006-12-13       Impact factor: 9.079

Review 5.  Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine.

Authors:  Robert C Brunham; José Rey-Ladino
Journal:  Nat Rev Immunol       Date:  2005-02       Impact factor: 53.106

6.  Glycerol monolaurate prevents mucosal SIV transmission.

Authors:  Qingsheng Li; Jacob D Estes; Patrick M Schlievert; Lijie Duan; Amanda J Brosnahan; Peter J Southern; Cavan S Reilly; Marnie L Peterson; Nancy Schultz-Darken; Kevin G Brunner; Karla R Nephew; Stefan Pambuccian; Jeffrey D Lifson; John V Carlis; Ashley T Haase
Journal:  Nature       Date:  2009-03-04       Impact factor: 49.962

7.  Mucosal and peripheral immune responses to chlamydial heat shock proteins in women infected with Chlamydia trachomatis.

Authors:  T Agrawal; V Vats; S Salhan; A Mittal
Journal:  Clin Exp Immunol       Date:  2007-06       Impact factor: 4.330

8.  Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission.

Authors:  Mary E Klotman; Aprille Rapista; Natalia Teleshova; Amanda Micsenyi; Gary A Jarvis; Wuyuan Lu; Edith Porter; Theresa L Chang
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

9.  A distinct cellular profile is seen in the human endocervix during Chlamydia trachomatis infection.

Authors:  Mercedes Ficarra; Joyce S A Ibana; Constance Poretta; Liang Ma; Leann Myers; Stephanie N Taylor; Sheila Greene; Barbara Smith; Michael Hagensee; David H Martin; Alison J Quayle
Journal:  Am J Reprod Immunol       Date:  2008-11       Impact factor: 3.886

10.  17Beta-estradiol suppresses TLR3-induced cytokine and chemokine production in endometrial epithelial cells.

Authors:  Margaret J Lesmeister; Rebecca L Jorgenson; Steven L Young; Michael L Misfeldt
Journal:  Reprod Biol Endocrinol       Date:  2005-12-29       Impact factor: 5.211

View more
  7 in total

1.  Identification of preferential CD4+ T-cell targets for HIV infection in the cervix.

Authors:  V R Joag; L R McKinnon; J Liu; S T Kidane; M H Yudin; B Nyanga; S Kimwaki; K E Besel; J O Obila; S Huibner; J O Oyugi; J Arthos; O Anzala; J Kimani; M A Ostrowski; R Kaul
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

2.  HIV vaccine trial exploits a dual and central role for innate immunity.

Authors:  Deborah Heydenburg Fuller; Laura E Richert-Spuhler; Nichole R Klatt
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

Review 3.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

4.  Individual and Population Level Impact of Key HIV Risk Factors on HIV Incidence Rates in Durban, South Africa.

Authors:  Gita Ramjee; Suri Moonsamy; Nathlee Samantha Abbai; Handan Wand
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

5.  Depot medroxyprogesterone acetate administration increases cervical CCR5+CD4+ T cells and induces immunosuppressive milieu at the cervicovaginal mucosa.

Authors:  Carley Tasker; Vanessa Pizutelli; Yungtai Lo; Bharat Ramratnam; Natalie E Roche; Theresa L Chang
Journal:  AIDS       Date:  2020-04-01       Impact factor: 4.632

Review 6.  Influence of the tryptophan-indole-IFNγ axis on human genital Chlamydia trachomatis infection: role of vaginal co-infections.

Authors:  Ashok Aiyar; Alison J Quayle; Lyndsey R Buckner; Shardulendra P Sherchand; Theresa L Chang; Arnold H Zea; David H Martin; Robert J Belland
Journal:  Front Cell Infect Microbiol       Date:  2014-06-03       Impact factor: 5.293

7.  Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban.

Authors:  Nathlee Samantha Abbai; Handan Wand; Gita Ramjee
Journal:  BMC Womens Health       Date:  2016-03-19       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.